BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551]
URL: https://www.wjgnet.com/1007-9327/full/v25/i44/6551.htm
Number Citing Articles
1
Marta Giachello, Lucia Leporatti, Rosella Levaggi, Marcello Montefiori. The illness trap: The impact of disability benefits on willingness to receive HCV treatmentEconomics & Human Biology 2024; 52: 101352 doi: 10.1016/j.ehb.2024.101352
2
Xizi Deng, Zhiwei Liang, Weiping Cai, Feng Li, Junbin Li, Fengyu Hu, Yun Lan. Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, ChinaVirology Journal 2022; 19(1) doi: 10.1186/s12985-022-01849-4
3
Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin, Tao Han, Yuemin Nan, Liaoyun Zhang, Alessandro Granito. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter StudyCanadian Journal of Gastroenterology and Hepatology 2022; 2022: 1 doi: 10.1155/2022/7395506
4
Mi Seon Park, Young-Mo Yang, Ki Hyun Park, Hyonok Yoon, Ju Sin Kim, Eun Joo Choi. Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care HospitalKorean Journal of Clinical Pharmacy 2022; 32(3): 191 doi: 10.24304/kjcp.2022.32.3.191
5
Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi. Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dosePharmacology Research & Perspectives 2021; 9(4) doi: 10.1002/prp2.811
6
Hui Jun Zhou, Jing Cao, Hui Shi, Nasheen Naidoo, Sherehe Semba, Pei Wang, Yi Fan Fan, Shui Cheng Zhu. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in ChinaFrontiers in Public Health 2021; 9 doi: 10.3389/fpubh.2021.779215
7
Tingting Mei, Xiaojie Huang, Shan Tang, Menglu Liu, Wenyan Zhang, Haibin Yu. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysisLipids in Health and Disease 2024; 23(1) doi: 10.1186/s12944-023-01957-2
8
Nahed Mohammed Hawsawi, Tamer Saber, Hussein M. Salama, Walaa S. Fouad, Howaida M. Hagag, Hayaa M. Alhuthali, Emad M. Eed, Taisir Saber, Khadiga A. Ismail, Hesham H. Al Qurashi, Samir Altowairqi, Mohmmad Samaha, Dalia El-Hossary. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care HospitalTropical Medicine and Infectious Disease 2023; 8(2): 92 doi: 10.3390/tropicalmed8020092
9
Resha Dermawansyah Rusman, Nu’man AS Daud, Muhammad Luthfi Parewangi, Syakib Bakri, Andi Makbul Aman, Haerani Rasyid, Arifin Seweng, Akiko Syawalidhany Tahir. Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patientsEgyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00217-9
10
Huan-Keat Chan, Mohamed Azmi Hassali, Rosaida Md Said, Haniza Omar, Noor Aliza Abd Mutalib, Frederick Walter De Rozario, Muhammad Radzi Abu Hassan. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in MalaysiaHepatitis Monthly 2021; 21(3) doi: 10.5812/hepatmon.113226
11
Innocent Kamali, Dale A. Barnhart, Françoise Nyirahabihirwe, Jean de la Paix Gakuru, Mariam Uwase, Esdras Nizeyumuremyi, Stephen Walker, Christian Mazimpaka, Jean de Dieu Gatete, Jean Damascene Makuza, Janvier Serumondo, Fredrick Kateera, Jean d’Amour Ndahimana. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approachBMC Infectious Diseases 2021; 21(1) doi: 10.1186/s12879-021-05920-3
12
Heba Shawky, Reem El-Shenawy, Naiera M. Helmy. Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patientsHuman Antibodies 2021; 29(4): 263 doi: 10.3233/HAB-211504